Physician profile
Amanda Block
NPI 1588204390
$5,088.29
in general payments reported to CMS, 2019-2025
28 companies · $839 in 2025
The $839 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $1,062 · 2023: $1,186 · 2024: $765 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,018.38 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,004.99 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $755.50 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $391.35 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $289.89 | 2021-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $218.88 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $168.14 | 2021-2024 | Hyqvia |
| Alkermes, INC. | $129.69 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.21 | 2025 | Cobenfy |
| Alfasigma USA, INC. | $107.83 | 2022 | |
| Lundbeck LLC | $105.02 | 2021-2023 | Rexulti |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Vanda Pharmaceuticals INC. | $86.86 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $77.44 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $70.20 | 2022-2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $63.54 | 2024 | Carvykti |
| Supernus Pharmaceuticals, INC. | $51.72 | 2023-2025 | Qelbree |
| Axsome Therapeutics, INC. | $49.44 | 2022-2023 | Auvelity |
| Orexo US, INC. | $44.35 | 2021-2023 | Zubsolv |
| Jazz Pharmaceuticals INC. | $40.72 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $39.88 | 2021 | |
| Novo Nordisk INC | $36.28 | 2023 | Wegovy |
| Uswm, LLC | $34.93 | 2021 | |
| Indivior INC. | $20.54 | 2021 | |
| Almatica Pharma LLC | $19.58 | 2025 | Loreev Xr |
| Eisai INC. | $15.94 | 2021 | |
| Bausch Health US, LLC | $14.42 | 2024 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.